The United States Food and Drug Administration (USFDA) has classified the inspection of Aurobindo Pharma’s step-down wholly owned subsidiary -- Lannett Company LLC, located in Seymour, IN, USA, as official action indicated (OAI). The inspection was conducted from August 17, 2026 to August 21,2026. After the completion of inspection, the USFDA had issued four observations which it has responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.